Revlimid (Lenalidomide)
Launch:
Revlimid was launched by Celgene (now part of Bristol-Myers Squibb) in 2005.
Manufacturer:
Bristol-Myers Squibb
Global Sales in 2023:
Revlimid achieved global sales of approximately $13 billion in 2023.
Why It’s the Best:
Revlimid is an immunomodulatory drug used primarily in the treatment of multiple myeloma and certain types of lymphoma. Its ability to modify the immune system and inhibit the growth of cancer cells has made it a critical component of cancer therapy regimens. Revlimid’s long-term effectiveness in prolonging patient survival, particularly in multiple myeloma, has cemented its place as a top-selling drug.